This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (33)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmological Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Yves Lachkar, MD; Clive Migdal, MD; Surinda Dhanjil, MSc, RVT

Arch Ophthalmol. 1998;116:1591-1594.

Objective  To study the effect of a selective ₂-adrenoreceptor agonist, brimonidine tartrate, on ocular hemodynamics.

Subjects and Methods  Eighteen patients with ocular hypertension were enrolled in a prospective, randomized, double-masked study in which 0.2% brimonidine tartrate, administered twice daily, was compared with its vehicle in a crossover fashion. The effect on the ocular circulation was assessed by color Doppler ultrasound, which measured blood flow velocities (peak systolic and end diastolic velocities) in the central retinal, ophthalmic, nasal, and temporal ciliary arteries. The following tests were performed at 2 weekly intervals on both treatments, 0.2% brimonidine tartrate and the placebo: intraocular pressure, heart rate, blood pressure, and color Doppler ultrasound.

Results  Velocities and resistivity indices measured by color Doppler ultrasound in the ophthalmic artery, central retinal artery, nasal artery, and temporal ciliary arteries showed no statistically significant differences between the placebo and 0.2% brimonidine tartrate when compared with baseline values and between the groups. Intraocular pressure was decreased by 17.7% ± 9.5% with 0.2% brimonidine tartrate (vs 9% ± 8% with placebo).

Conclusion  The hemodynamics of the posterior segment of the eye as measured by color Doppler ultrasound do not appear to be altered by 2% brimonidine tartrate.

From the Glaucoma Department, The Western Eye Hospital (Drs Lachkar and Migdal), and the Vascular Surgery Department, St Mary's Hospital (Mr Dhanjil), London, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Experimental and Clinical Evidence for Brimonidine as an Optic Nerve and Retinal Neuroprotective Agent: An Evidence-Based Review
Saylor et al.
Arch Ophthalmol 2009;127:402-406.
ABSTRACT | FULL TEXT  

Brimonidine evokes heterogeneous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small
Rosa et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H231-H238.
ABSTRACT | FULL TEXT  

Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma
Liu et al.
Br. J. Ophthalmol. 2002;86:1236-1239.
ABSTRACT | FULL TEXT  

Potent {alpha}2A-Adrenoceptor-Mediated Vasoconstriction by Brimonidine in Porcine Ciliary Arteries
Wikberg-Matsson and Simonsen
IOVS 2001;42:2049-2055.
ABSTRACT | FULL TEXT  

Comparison of the Vasoactive Effects of the Docosanoid Unoprostone and Selected Prostanoids on Isolated Perfused Retinal Arterioles
Yu et al.
IOVS 2001;42:1499-1504.
ABSTRACT | FULL TEXT